# Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

> **NCT01190878** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 169 (actual)

## Conditions studied

- Ocular Inflammation

## Interventions

- **DRUG:** ISV-303
- **DRUG:** ISV-303
- **DRUG:** DuraSite Vehicle
- **DRUG:** Xibrom™

## Key facts

- **NCT ID:** NCT01190878
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190878, "Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01190878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*